Search Results

Motus GI Holdings, Inc. announced that the Pure-Vu Gen 4 Gastro and Colon system was featured during the 9th Ecuadorian Institute of Digestive Diseases Live Endoscopy Course 2023 at the Pentax Learning Center, which is considered one of the most important digestive medicine annual events held in the Latin American region with over 1,000 physicians registered.

Powered by a commitment to accelerating bold, emerging science, the Parker Institute for Cancer Immunotherapy continues to invest in the next generation of scientific leaders and their ambitious ideas for curative cancer treatments.

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma and head-and-neck cancer, with several readouts slated for the second half of 2025.

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host an investor call with a live Q&A on Monday, November 9th at 8:30 a.m. EST to provide additional details on the clinical and immune response data from the remaining GEN-009 Part B patients to be shared at the 35th Annual Meeting of The Society

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% weight reduction.

Chemotherapy-Induced Anemia Market Outlook 2025-2035: